Archemix and Merck KGaA Collaborates on Development and Marketing of Aptamer-Based Cancer Therapeutics
Archemix will receive an upfront payment and committed research funding of as much as $10 million.- Archemix also could receive milestones and royalty payments for products successfully commercialized under the collaboration.
- Archemix may participate in the co-promotion of products that result from the collaboration.
[Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies.]
Aptamers are a new class of anti-cancer drugs and where Archemix is a leader in its development. Merck being a leader in oncology drug development and marketing can put aptamers into the next level in cancer therapy.
Other financial terms were not disclosed.
Find more details from the press release.
Comment Preview